文献速递炎症性肠病

儿童炎症性肠病中抗TNF治疗使用率上升与儿童期手术切除率下降相关

Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood.
PubMed 文献 · Aliment Pharmacol Ther · 2019-01-09

研究分析1997至2017年Wessex地区825例儿童期起病炎症性肠病(PIBD)患者,抗TNF治疗使用率从5.1%升至27.1%(P=0.0001),手术切除率从7.1%降至1.5%(P=0.001),主要由克罗恩病切除率下降驱动(8.9%降至2.3%,P=0.001)。肛周手术和溃疡性结肠炎切除率无变化。抗TNF治疗起始于诊断后3年内者切除率低于较晚起始者(11.6% vs 28.6%,P=0.047)。

要点

  • 抗TNF治疗使用率从5.1%升至27.1%(2007-2017),P=0.0001。
  • 手术切除率从7.1%降至1.5%(P=0.001),主要由克罗恩病切除率下降驱动。
  • 抗TNF治疗起始于诊断后3年内者切除率低于较晚起始者(11.6% vs 28.6%,P=0.047)。

核心结论

  • 抗TNF治疗使用率显著上升,同时手术切除率下降。
  • 较年轻诊断的患者在儿童期仍接受手术。
  • 抗TNF治疗可能减少儿童期手术干预需求,从而影响PIBD自然病史。

研究设计与样本

  • 分析Wessex PIBD队列中1997至2017年诊断的儿童期起病炎症性肠病患者。
  • 共纳入825例儿童(498例克罗恩病,272例溃疡性结肠炎,55例IBD未分类),诊断时平均年龄13.6岁(范围1.6-17.6),女性占39.6%。
  • 分析儿童期(<18岁)抗TNF治疗使用率和每年手术率(切除和肛周手术),采用Pearson相关、多变量回归和Fisher精确检验。

主要发现

  • 抗TNF治疗患者比例从5.1%增至27.1%(2007-2017),P=0.0001。
  • 手术切除率从7.1%降至1.5%(P=0.001),克罗恩病切除率从8.9%降至2.3%(P=0.001)。
  • 肛周手术和溃疡性结肠炎切除率无变化。
  • 从诊断至切除的时间从1.6年延长至2.8年(P=0.028),但切除时平均年龄无变化。
  • 最近5年儿童期接受切除的患者诊断年龄更小(2007-2011年13.1岁,2013-2017年11.9岁,P=0.014)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-tumour necrosis factor-α (anti-TNF) therapy use has risen in paediatric-onset inflammatory bowel disease (PIBD). Whether this has translated into preventing/delaying childhood surgery is uncertain. The Wessex PIBD cohort was analysed for trends in anti-TNF-therapy and surgery. AIM: To assess patients diagnosed with PIBD within Wessex from 1997 to 2017. The prevalence of anti-TNF-therapy and yearly surgery rates (resection and perianal) during childhood (<18 years) were analysed (Pearson's correlation, multivariate regression, Fisher's exact). RESULTS: Eight-hundred-and-twenty-five children were included (498 Crohn's disease, 272 ulcerative colitis, 55 IBD-unclassified), mean age at diagnosis 13.6 years (1.6-17.6), 39.6% female. The prevalence of anti-TNF-treated patients increased from 5.1% to 27.1% (2007-2017), P = 0.0001. Surgical resection-rate fell (7.1%-1.5%, P = 0.001), driven by a decrease in Crohn's disease resections (8.9%-2.3%, P = 0.001). Perianal surgery and ulcerative colitis resection-rates were unchanged. Time from diagnosis to resection increased (1.6-2.8 years, P = 0.028) but mean age at resection was unchanged. Patients undergoing resections during childhood were diagnosed at a younger age in the most recent 5 years (2007-2011 = 13.1 years, 2013-2017 = 11.9 years, P = 0.014). Resection-rate in anti-TNF-therapy treated (16.1%) or untreated (12.2%) was no different (P = 0.25). Patients started on anti-TNF-therapy <3 years post-diagnosis (11.6%) vs later (28.6%) had a reduction in resections, P = 0.047. Anti-TNF-therapy prevalence was the only significant predictor of resection-rate using multivariate regression (P = 0.011). CONCLUSIONS: The prevalence of anti-TNF-therapy increased significantly, alongside a decrease in surgical resection-rate. Patients diagnosed at younger ages still underwent surgery during childhood. Anti-TNF-therapy may reduce the need for surgical intervention in childhood, thereby influencing the natural history of PIBD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ashton JJ, Borca F, Mossotto E, et al. Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood. Aliment Pharmacol Ther. 2019. PMID: 30628109. doi:10.1111/apt.15094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。